36 research outputs found
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
Get PDFBACKGROUND: CYT997 is a novel microtubule inhibitor and vascular-disrupting agent with marked preclinical anti-tumour activity. METHODS: This phase I dose-escalation study assessed the safety, tolerability, pharmacokinetics and pharmacodynamics of CYT997 administered by continuous intravenous infusion over 24 h every 3 weeks to patients with advanced solid tumours
Opposed circulating plasma levels of endothelin-1 and C-type natriuretic peptide in children with Plasmodium falciparum malaria
Get PDF
An In Vivo Lapine Model for Impact-Induced Injury and Osteoarthritic Degeneration of Articular Cartilage
No full text
Has acne increased? Prevalence of acne history among university students between 1948 and 1968. The Glasgow Cohort Study
No full textTrends in resting pulse rate among students attending Glasgow University between 1948 and 1968: analyses of cross sectional surveys
No full textType 2 diabetes in grandparents and birth weight in offspring and grandchildren in the ALSPAC study
No full text
